OpGen Presents Rapid Acuitas Genetic Test Data at Advances in Genome Biology and Technology Meeting
“These data highlight the unique ability of our rapid testing approach in development to considerably reduce the time necessary to acquire predicted resistance results compared to traditional antibiotic susceptibility tests (AST). The presented data suggest this rapid testing approach predicts bacterial antibiotic resistance using an algorithm based on minimum inhibitory concentration values with the average positive predictive values greater than 90% for six Gram-negative species commonly known to harbor resistance genes (E. coli, E. cloacae, E. aerogenes, A. baumannii, K. pneumoniae and P.aeruginosa). By identifying and using accurate gene profiles, we anticipate that actionable results can be generated within hours instead of days,” said
The poster titled: “Development of a Rapid Molecular Antibiotic Susceptibility Test,” was presented by
- Combined experimental results were used to develop statistical models for predicting phenotypic resistance for several antibiotics based on detection of resistance for several antibiotics based on detection of resistance genes.
- Genotypic algorithms predicted phenotypic resistance with average positive predictive values ranging from 92% to 97%.
- Average sensitivities for each species ranged from 78% to 98% while average specificity ranged from 74% to 91%.
“These preliminary results illustrate our ability to develop algorithms that can leverage resistance gene profiles to predict phenotypic resistance accurately,” said Dr. Walker. “These initial data are very encouraging. We anticipate further improvements in test performance as we complete our planned genomic and phenotypic testing of approximately 10,000 multi-drug resistant organisms in the coming months.”
This press release includes statements relating to the company's rapid testing product in development. These statements and other statements regarding our future plans and goals constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control, and which may cause results to differ materially from expectations. Factors that could cause our results to differ materially from those described include, but are not limited to, our ability to successfully, timely and cost-effectively develop, seek and obtain regulatory approval for and commercialize our mAST™ product in development, the rate of adoption of our products and services by hospitals and other healthcare providers, and other economic and competitive factors. For a discussion of the most significant risks and uncertainties associated with
Michael FarmerDirector, Marketing 240-813-1284 firstname.lastname@example.org InvestorRelations@opgen.com OpGen Investor and Media Contact: MacDougall Biomedical Communications Cammy Duong781-591-3443 email@example.com